Description: ImmunoPrecise Antibodies Ltd. engages in the antibody production and related services in the United States, Canada, Europe, and internationally. Its services include B cell sorting, screening and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multispecies antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing, purification in gram scale levels, and characterization and validation; antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with screening and clone-picking; cryopreservation; affinity measurements, functional assays, and epitope mapping and binning; and modeling, design, and manufacturing of custom antigen. The company has a collaboration with University of Victoria to develop a saliva-based antibody-based test for the detection and screening of COVID-19; Zymeworks Inc. for the development of multiple antibody candidates to fight COVID-19; and National Research Council of Canada's Human Health Therapeutics Research Centre to develop neutralizing PolyTope antibodies against SARS-CoV-2, as well as a research partnership with Mila. ImmunoPrecise Antibodies Ltd. was founded in 1989 and is headquartered in Fargo, North Dakota.
Home Page: www.ipatherapeutics.com
IPA Technical Analysis
3204–4464 Markham Street
Victoria,
BC
V8Z 7X8
Canada
Phone:
250 483 0308
Officers
| Name | Title |
|---|---|
| Dr. Jennifer Lynne Bath Ph.D. | CEO, Pres & Non-Independent Director |
| Mr. Brad McConn | Chief Financial Officer |
| Dr. Ilse Roodink | Chief Scientific Officer |
| Mr. David E. Orton | Chief Operating Officer |
| Ms. Carla Dahl | VP of Marketing |
| Dr. Barry Neil Duplantis | VP of Client Relations |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.7541 |
| Price-to-Sales TTM: | 6.2771 |
| IPO Date: | 2017-01-03 |
| Fiscal Year End: | April |
| Full Time Employees: | 85 |